Drug intelligence / Profile preview

OriC902

Development stage: Phase 1
Lead developer: OriCell Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

OriC902 is an investigational autologous chimeric antigen receptor T cell (CAR-T) therapy targeting glypican-3 (GPC3), a protein commonly overexpressed in certain liver cancers. It is being developed for the treatment of advanced hepatocellular carcinoma (HCC) and other GPC3-positive neoplasms. The therapy involves engineering a patient's own T cells to express a CAR that recognizes and binds to GPC3 on tumor cells, enabling targeted immune-mediated destruction of cancer cells. OriC902 is currently in Phase 1 clinical trials, with its development led by OriCell Therapeutics.

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on OriC902.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OriC902.

Explore the full profile